RESUMO
The human GPCR family comprises circa 800 members, activated by hundreds of thousands of compounds. Bitter taste receptors, TAS2Rs, constitute a large and distinct subfamily, expressed orally and extra-orally and involved in physiological and pathological conditions. TAS2R14 is the most promiscuous member, with over 150 agonists and 3 antagonists known prior to this study. Due to the scarcity of inhibitors and to the importance of chemical probes for exploring TAS2R14 functions, we aimed to discover new ligands for this receptor, with emphasis on antagonists. To cope with the lack of experimental structure of the receptor, we used a mixed experimental/computational methodology which iteratively improved the performance of the predicted structure. The increasing number of active compounds, obtained here through experimental screening of FDA-approved drug library, and through chemically synthesized flufenamic acid derivatives, enabled the refinement of the binding pocket, which in turn improved the structure-based virtual screening reliability. This mixed approach led to the identification of 10 new antagonists and 200 new agonists of TAS2R14, illustrating the untapped potential of rigorous medicinal chemistry for TAS2Rs. 9% of the ~ 1800 pharmaceutical drugs here tested activate TAS2R14, nine of them at sub-micromolar concentrations. The iterative framework suggested residues involved in the activation process, is suitable for expanding bitter and bitter-masking chemical space, and is applicable to other promiscuous GPCRs lacking experimental structures.
Assuntos
Receptores Acoplados a Proteínas G , Paladar , Humanos , Paladar/fisiologia , Receptores Acoplados a Proteínas G/metabolismo , Ligantes , Reprodutibilidade dos Testes , Ligação ProteicaRESUMO
Morphine is an alkaloid from the opium poppy used to treat pain. The potentially lethal side effects of morphine and related opioids-which include fatal respiratory depression-are thought to be mediated by µ-opioid-receptor (µOR) signalling through the ß-arrestin pathway or by actions at other receptors. Conversely, G-protein µOR signalling is thought to confer analgesia. Here we computationally dock over 3 million molecules against the µOR structure and identify new scaffolds unrelated to known opioids. Structure-based optimization yields PZM21-a potent Gi activator with exceptional selectivity for µOR and minimal ß-arrestin-2 recruitment. Unlike morphine, PZM21 is more efficacious for the affective component of analgesia versus the reflexive component and is devoid of both respiratory depression and morphine-like reinforcing activity in mice at equi-analgesic doses. PZM21 thus serves as both a probe to disentangle µOR signalling and a therapeutic lead that is devoid of many of the side effects of current opioids.
Assuntos
Analgésicos Opioides/efeitos adversos , Analgésicos Opioides/química , Descoberta de Drogas , Receptores Opioides mu/agonistas , Tiofenos/química , Tiofenos/farmacologia , Ureia/análogos & derivados , Analgesia/métodos , Analgésicos Opioides/farmacologia , Animais , Subunidades alfa Gi-Go de Proteínas de Ligação ao GTP/metabolismo , Células HEK293 , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Simulação de Acoplamento Molecular , Dor/tratamento farmacológico , Receptores Opioides mu/deficiência , Receptores Opioides mu/genética , Receptores Opioides mu/metabolismo , Compostos de Espiro/farmacologia , Relação Estrutura-Atividade , Tiofenos/efeitos adversos , Ureia/efeitos adversos , Ureia/química , Ureia/farmacologiaRESUMO
G protein-coupled receptors (GPCRs) mediate most of our physiological responses to hormones, neurotransmitters and environmental stimulants. Besides human senses like vision and olfaction, taste perception is mostly mediated by GPCRs. Hence, the bitter taste receptor family TAS2R comprises 25 distinct receptors and plays a key role in food acceptance and drug compliance. The TAS2R14 subtype is the most broadly tuned bitter taste receptor, recognizing a range of chemically highly diverse agonists. Besides other tissues, it is expressed in human airway smooth muscle and may represent a novel drug target for airway diseases. Several natural products as well as marketed drugs including flufenamic acid have been identified to activate TAS2R14, but higher potency ligands are needed to investigate the ligand-controlled physiological function and to facilitate the targeted modulate for potential future clinical applications. A combination of structure-based molecular modeling with chemical synthesis and in vitro profiling recently resulted in new flufenamic acid agonists with improved TAS2R14 potency and provided a validated and refined structural model of ligand-TAS2R14 interactions, which can be applied for future drug design projects.
RESUMO
Human bitter taste receptors (TAS2Rs) are a subfamily of 25 G protein-coupled receptors that mediate bitter taste perception. TAS2R14 is the most broadly tuned bitter taste receptor, recognizing a range of chemically diverse agonists with micromolar-range potency. The receptor is expressed in several extra-oral tissues and is suggested to have physiological roles related to innate immune responses, male fertility, and cancer. Higher potency ligands are needed to investigate TAS2R14 function and to modulate it for future clinical applications. Here, a structure-based modeling approach is described for the design of TAS2R14 agonists beginning from flufenamic acid, an approved non-steroidal anti-inflammatory analgesic that activates TAS2R14 at sub-micromolar concentrations. Structure-based molecular modeling was integrated with experimental data to design new TAS2R14 agonists. Subsequent chemical synthesis and in vitro profiling resulted in new TAS2R14 agonists with improved potency compared to the lead. The integrated approach provides a validated and refined structural model of ligand-TAS2R14 interactions and a general framework for structure-based discovery in the absence of closely related experimental structures.
Assuntos
Receptores Acoplados a Proteínas G/agonistas , Percepção Gustatória/fisiologia , Paladar/fisiologia , Linhagem Celular , Fertilidade/fisiologia , Células HEK293 , Humanos , Imunidade Inata/fisiologia , Ligantes , Modelos Moleculares , Neoplasias/metabolismoRESUMO
In recent studies, major depressive disorder (MDD) was linked to an increase in acid sphingomyelinase (ASM) activity. Several drugs that are commonly used to treat MDD functionally inhibit the lysosomal enzyme ASM and are called functional inhibitors of ASM (FIASMAs). These drugs are classified as cationic amphiphilic drugs (CADs) that influence the catalytic activities of different lysosomal enzymes. This action results in the side effect of phospholipidosis (PLD), which describes a detrimental increase in the phospholipid content in lysosomes. FIASMAs differ only slightly in their physico-chemical properties, but their effects on ASM activity and induction of the lysosomal phospholipid content vary significantly. In this study, we systematically induced minor chemical modifications to the FIASMAs imipramine, desipramine and fluoxetine. We generated a library of 45 new CADs with slightly different log P (logarithmic partition coefficient) and pKa (logarithmic acid dissociation constant) values. The effects of the compounds on the ASM activity and lysosomal phospholipid content were assessed in cell culture assays. We identified four compounds with beneficial effects, i.e., increased ASM activity inhibition and reduced PLD induction compared with the original drugs. The compounds HT04, RH272B and RH272D outperformed the original imipramine, whereas RH281A performed better than desipramine. Thus, minor chemical variations of CADs impact lysosomal metabolism in a specific manner and can lead to antidepressant drugs with less deleterious side effects.
Assuntos
Desipramina/farmacologia , Fluoxetina/farmacologia , Imipramina/farmacologia , Lisossomos/efeitos dos fármacos , Fosfolipídeos/metabolismo , Esfingomielina Fosfodiesterase/metabolismo , Antidepressivos/farmacologia , Linhagem Celular Tumoral , Humanos , Lisossomos/metabolismoRESUMO
Recent breakthroughs in GPCR structural biology have significantly increased our understanding of drug action at these therapeutically relevant receptors, and this will undoubtedly lead to the design of better therapeutics. In recent years, crystal structures of GPCRs from classes A, B, C and F have been solved, unveiling a precise snapshot of ligand-receptor interactions. Furthermore, some receptors have been crystallized in different functional states in complex with antagonists, partial agonists, full agonists, biased agonists and allosteric modulators, providing further insight into the mechanisms of ligand-induced GPCR activation. It is now obvious that there is enormous diversity in the size, shape and position of the ligand binding pockets in GPCRs. In this review, we summarise the current state of solved GPCR structures, with a particular focus on ligand-receptor interactions in the binding pocket, and how this can contribute to the design of GPCR ligands with better affinity, subtype selectivity or efficacy.
Assuntos
Desenho de Fármacos , Receptores Acoplados a Proteínas G/química , Receptores Acoplados a Proteínas G/metabolismo , Química Farmacêutica/métodos , Cristalografia por Raios X , Humanos , Ligantes , Conformação Proteica , Receptores Adrenérgicos beta/química , Receptores Adrenérgicos beta/metabolismoRESUMO
Homodimers of dopamine D2-like receptors are suggested to be of particular importance in the pathophysiology of schizophrenia and, thus, serve as promising targets for the discovery of atypical antipsychotics. This study describes the development of a series of novel bivalent molecules with a pharmacophore derived from the dopamine receptor antagonist haloperidol. These dimers were investigated in comparison to their monomeric analogues for their D2long, D2short, D3, and D4 receptor binding and the ability to bridge two neighboring receptor protomers. Radioligand binding studies provided diagnostic insights when Hill slopes close to two for the bivalent ligand 13 incorporating 22 spacer atoms and a comparative analysis with monovalent control ligands indicated a bivalent binding mode with a simultaneous occupancy of two neighboring binding sites.
Assuntos
Haloperidol/farmacologia , Receptores de Dopamina D2/metabolismo , Sítios de Ligação/efeitos dos fármacos , Relação Dose-Resposta a Droga , Haloperidol/síntese química , Haloperidol/química , Humanos , Ligantes , Estrutura Molecular , Relação Estrutura-AtividadeRESUMO
Employing the D4 selective phenylpiperazine 2 as a lead compound, planar chiral analogs with paracyclophane substructure were synthesized and evaluated for their ability to bind and activate dopamine receptors. The study revealed that the introduction of a [2.2]paracyclophane moiety is tolerated by dopamine receptors of the D2 family. Subtype selectivity for D4 and ligand efficacy depend on the absolute configuration of the test compounds. Whereas the achiral single-layered lead 2 and the double-layered paracyclophane (R)-3 showed partial agonist properties, the enantiomer (S)-3 behaved as a neutral antagonist.
Assuntos
Antagonistas de Dopamina/química , Antagonistas de Dopamina/farmacologia , Piperazinas/química , Piperazinas/farmacologia , Receptores de Dopamina D4/antagonistas & inibidores , Animais , Células CHO , Cricetinae , Humanos , Receptores de Dopamina D4/metabolismo , EstereoisomerismoRESUMO
The bitter taste receptor TAS2R14 is a G protein-coupled receptor that is found on the tongue as well as in the human airway smooth muscle and other extraoral tissues. Because its activation causes bronchodilatation, TAS2R14 is a potential target for the treatment of asthma or chronic obstructive pulmonary disease. Structural variations of flufenamic acid, a nonsteroidal anti-inflammatory drug, led us to 2-aminopyridines showing considerable efficacy and potency in an IP1accumulation assay. In combination with an exchange of the carboxylic moiety by a tetrazole unit, a set of promising new TAS2R14 agonists was developed. The most potent ligand 28.1 (EC50 = 72 nM) revealed a six-fold higher potency than flufenamic acid and a maximum efficacy of 129%. Besides its unprecedented TAS2R14 activation, 28.1 revealed marked selectivity over a panel of 24 non-bitter taste human G protein-coupled receptors.
Assuntos
Ácido Flufenâmico , Paladar , Humanos , Receptores Acoplados a Proteínas G/agonistas , Músculo LisoRESUMO
Based on the dopamine D(4) receptor partial agonist FAUC 3019, a series of azulenylmethylpiperazines was synthesized and affinities for the monoaminergic GPCRs including dopamine, serotonin, histamine and α-adrenergic receptor subtypes were determined. Ligand efficacies of the most promising test compounds revealed the N,N-dimethylaminomethyl substituted azulene 11 to be the most potent D(4) partial agonist (EC(50)=0.41 nM). This candidate was investigated for its ability to promote penile erection. Applying an in vivo animal model, test compound 11 turned out to stimulate penile erection in male rats with superior potency in low concentrations when compared to apomorphine.
Assuntos
Azulenos/química , Azulenos/uso terapêutico , Disfunção Erétil/tratamento farmacológico , Metilaminas/uso terapêutico , Animais , Azulenos/síntese química , Humanos , Cinética , Masculino , Metilaminas/síntese química , Metilaminas/química , Ratos , Receptores Dopaminérgicos/química , Receptores Dopaminérgicos/metabolismo , Receptores de Dopamina D4/agonistas , Receptores de Dopamina D4/metabolismo , Receptores Histamínicos/química , Receptores Histamínicos/metabolismo , SuínosRESUMO
Merging two arylamidoalkyl substituted phenylpiperazines as prototypical recognition elements for dopamine D(2)-like receptors by oligoethylene glycol linkers led to a series of bivalent ligands. These dimers were investigated in comparison to their monomeric analogues for their dopamine D(2long), D(2short), D(3) and D(4) receptor binding. Radioligand binding experiments revealed strong bivalent effects for some para-substituted benzamide derivatives. For the D(3) subtype, the target compounds 32, 34 and 36 showed an up to 70-fold increase of affinity and a substantial enhancement of subtype selectivity when compared to the monovalent analogue 24. Analysis of the binding curves displayed Hill slopes very close to one indicating that the bivalent ligands displace 1equiv of radioligand. Obviously, the two pharmacophores occupy an orthosteric and an allosteric binding site rather than adopting a receptor-bridging binding mode.
Assuntos
Benzamidas/síntese química , Sondas Moleculares/química , Piperazinas/síntese química , Receptores de Dopamina D2/metabolismo , Benzamidas/química , Antagonistas dos Receptores de Dopamina D2 , Etilenoglicol/química , Marcação por Isótopo , Ligantes , Sondas Moleculares/metabolismo , Piperazinas/química , Piperazinas/metabolismo , Ligação Proteica , Receptores de Dopamina D3/antagonistas & inibidores , Receptores de Dopamina D3/metabolismo , Receptores de Dopamina D4/antagonistas & inibidores , Receptores de Dopamina D4/metabolismoRESUMO
BACKGROUND: The therapeutic effects of antipsychotic drugs (APDs) are mainly attributed to their postsynaptic inhibitory functions on the dopamine D2 receptor, which, however, cannot explain the delayed onset of full therapeutic efficacy. It was previously shown that APDs accumulate in presynaptic vesicles during chronic treatment and are released like neurotransmitters in an activity-dependent manner triggering an auto-inhibitory feedback mechanism. Although closely mirroring therapeutic action onset, the functional consequence of the APD accumulation process remained unclear. AIMS: Here we tested whether the accumulation of the APD haloperidol (HAL) is required for full therapeutic action in psychotic-like rats. METHODS: We designed a HAL analog compound (HAL-F), which lacks the accumulation property of HAL, but retains its postsynaptic inhibitory action on dopamine D2 receptors. RESULTS/OUTCOMES: By perfusing LysoTracker fluorophore-stained cultured hippocampal neurons, we confirmed the accumulation of HAL and the non-accumulation of HAL-F. In an amphetamine hypersensitization psychosis-like model in rats, we found that subchronic intracerebroventricularly delivered HAL (0.1 mg/kg/day), but not HAL-F (0.3-1.5 mg/kg/day), attenuates psychotic-like behavior in rats. CONCLUSIONS/INTERPRETATION: These findings suggest the presynaptic accumulation of HAL may serve as an essential prerequisite for its full antipsychotic action and may explain the time course of APD action. Targeting accumulation properties of APDs may, thus, become a new strategy to improve APD action.
Assuntos
Antipsicóticos/farmacologia , Haloperidol/farmacologia , Terminações Pré-Sinápticas , Transtornos Psicóticos , Vesículas Sinápticas/fisiologia , Animais , Células Cultivadas , Antagonistas dos Receptores de Dopamina D2/farmacologia , Sistemas de Liberação de Medicamentos/métodos , Hipocampo/metabolismo , Hipocampo/patologia , Potenciais Pós-Sinápticos Inibidores , Terminações Pré-Sinápticas/efeitos dos fármacos , Terminações Pré-Sinápticas/fisiologia , Terminações Pré-Sinápticas/ultraestrutura , Transtornos Psicóticos/tratamento farmacológico , Transtornos Psicóticos/metabolismo , Ratos , Receptores de Dopamina D2/metabolismoRESUMO
Dopamine is a neurotransmitter of great physiological relevance. Disorders in dopaminergic signal transduction are associated with psychiatric and neurological pathologies such as Parkinson's disease, schizophrenia and substance abuse. Therefore, a detailed understanding of dopaminergic neurotransmission may provide access to novel therapeutic strategies for the treatment of these diseases. Caged compounds with photoremovable groups represent molecular tools to investigate a biological target with high spatiotemporal resolution. Based on the crystal structure of the D3 receptor in complex with eticlopride, we have developed caged D2/D3 receptor ligands by rational design. We initially found that eticlopride, a widely used D2/D3 receptor antagonist, was photolabile and therefore is not suitable for caging. Subtle structural modification of the pharmacophore led us to the photostable antagonist dechloroeticlopride, which was chemically transformed into caged ligands. Among those, the 2-nitrobenzyl derivative 4 (MG307) showed excellent photochemical stability, pharmacological behavior and decaging properties when interacting with dopamine receptor-expressing cells.
Assuntos
Antagonistas de Dopamina , Desenvolvimento de Medicamentos , Receptores de Dopamina D2 , Receptores de Dopamina D3 , Antagonistas de Dopamina/síntese química , Antagonistas de Dopamina/química , Antagonistas dos Receptores de Dopamina D2 , Desenho de Fármacos , Estabilidade de Medicamentos , Humanos , Ligantes , Conformação Molecular , Doença de Parkinson/tratamento farmacológico , Doença de Parkinson/etiologia , Processos FotoquímicosRESUMO
Synthesis, biological investigations and molecular docking studies of nonantibiotic and nontetracyclic inducers that feature a minimal key motif of the natural lead tetracycline are presented. The diarylpropane-1,3-dione motif was identified as the minimal substructure responsible for TetR induction by tetracyclines. The first nontetracyclic surrogates of the natural tetracyclines displayed significant inducing effects for TetR(BD)S135L, whereby the chlorohydroxyphenyl-substituted beta-diketone 31 displayed the highest activity. Interestingly, antibiotic activity could not be detected for 31. Homology modeling based on the X-ray structure of 7-chlorotetracycline bound to TetR indicated analogous binding modes for the natural inducer and the synthetic diarylpropane-1,3-dione derivatives.
Assuntos
Antibacterianos/síntese química , Chalconas/química , Proteínas Repressoras/metabolismo , Tetraciclinas/síntese química , Antibacterianos/química , Antibacterianos/farmacologia , Simulação por Computador , Cristalografia por Raios X , Conformação Molecular , Ligação Proteica , Relação Estrutura-Atividade , Tetraciclinas/química , Tetraciclinas/farmacologiaRESUMO
Taking advantage of our click chemistry based methodology to construct novel SPOS (solid phase organic synthesis) resins, the triazolylmethyl linked catechol 6a was discovered, which is readily available via copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC) of azidomethyl substituted polystyrene with O-propargylcatechol and can be applied for the parallel synthesis of N-phenyltriazole carboxamides. As a proof-of-concept, a 'catch-and-release' strategy could be successfully applied for a parallel synthesis of dopaminergic phenyltriazoles of type 2. A focused model library of 20 test compounds revealing three points of diversity was generated by a three-step SPOS approach. Product purification was performed employing a solid-supported carboxylic acid anhydride as a scavenger. GPCR-ligand binding screening revealed dopamine D3 receptor ligands with K(i) values in the single digit nanomolar range.
Assuntos
Adrenérgicos/síntese química , Adrenérgicos/farmacologia , Receptores Dopaminérgicos/metabolismo , Triazóis/química , Triazóis/síntese química , Triazóis/farmacologia , Adrenérgicos/química , Animais , Ligação Competitiva , Células CHO , Técnicas de Química Combinatória , Cricetinae , Cricetulus , Humanos , Ligantes , Estrutura Molecular , Fenóis/química , Ligação Proteica , Receptores de Dopamina D3/metabolismo , SuínosRESUMO
A series of fluoro-substituted analogs structurally derived from the aminomethyl-substituted pyrazolo[1,5- a]pyridine lead compounds 9 (FAUC 113) and 10 (FAUC 213) were synthesized and evaluated as high-affinity D 4 receptor (D 4R) ligands ( 3a- 3h, K i = 1.3-28 nM). The para-fluoroethoxy-substituted derivatives 3f and 3h revealed an outstanding D 4 subtype selectivity of more than 3 orders of magnitude over both congeners D 2 and D 3 combined with inverse agonism at D 4R. The corresponding (18)F-labeled radioligands revealed high serum stability in vitro and log P values of 2-3. In vitro rat brain autoradiography showed specific binding of [ (18)F]3h in distinct brain regions, including the gyrus dentate of the hippocampus, that were inhibited by both eticlopride (65-80%) and the selective D 4R antagonist 10 (78-93%). The observed binding pattern was mainly consistent with the known D 4R distribution in the rat brain. Thus, [(18)F]3h (FAUC F41) represents a potential radioligand for studying the D 4R in vivo by positron emission tomography (PET).
Assuntos
Radioisótopos de Flúor/química , Tomografia por Emissão de Pósitrons , Pirazóis , Piridinas , Compostos Radiofarmacêuticos , Receptores de Dopamina D4/efeitos dos fármacos , Animais , Encéfalo/diagnóstico por imagem , Desenho de Fármacos , Avaliação Pré-Clínica de Medicamentos , Feminino , Humanos , Marcação por Isótopo/métodos , Ligantes , Estrutura Molecular , Pirazóis/síntese química , Pirazóis/farmacologia , Piridinas/síntese química , Piridinas/farmacologia , Ensaio Radioligante , Compostos Radiofarmacêuticos/síntese química , Compostos Radiofarmacêuticos/farmacologia , Ratos , Ratos Sprague-Dawley , EstereoisomerismoRESUMO
Employing D4 selective azaindoles as lead compounds, a focused library of the carbocyclic arene bioisosteres 1 was synthesized when we took advantage of the click chemistry derived triazolylmethyl acrylate resin 2. Ligand binding assays on monoaminergic GPCRs led to SARs that indicated further lead structure optimizations when the attachment of alkoxy substituents provided both an improvement of the biological properties and the opportunity to introduce (18)F as a radioisotope. Finally, radiosynthesis resulted in formation of the radioligand [(18)F]7h that showed optimal logD(7.4) of 2.8 and was determined to be highly stable in human serum. Thus, [(18)F]7h represents a promising dopamine D4 selective radioligand for positron emission tomography (PET).
Assuntos
Compostos Aza/síntese química , Compostos Aza/farmacocinética , Técnicas de Química Combinatória , Indóis/síntese química , Indóis/farmacocinética , Compostos Radiofarmacêuticos/síntese química , Compostos Radiofarmacêuticos/farmacocinética , Receptores de Dopamina D4/efeitos dos fármacos , Compostos Aza/química , Radioisótopos de Flúor , Humanos , Indóis/química , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos/química , Relação Estrutura-AtividadeRESUMO
Human transmissible neurodegenerations including Creutzfeldt-Jakob disease are unique, since they are caused by prions, an infectious agent that replicates without nucleic acids but instead by inducing conversion of a host-resident normal prion protein to a misfolded conformational isoform. For pharmacotherapy of these unusual diseases, tricyclic heterocyclic compounds such as quinacrine have been considered, but with ambiguous success in vivo, so far. On the basis of the synergistic antiprion effects of quinacrine and iminodibenzyl derivatives, we introduce a novel class of potential pharmaceuticals representing structural chimeras of quinacrine and imipramine analogues. We describe the chemical synthesis and bioassays of a focused library of these compounds. The most potent target compound 2a revealed an EC(50) value of 20 nM determined with a cell model of prion disease, thus substantially improving the antiprion efficacy of quinacrine.
Assuntos
Acridinas/síntese química , Acridinas/farmacologia , Imipramina/análogos & derivados , Imipramina/síntese química , Príons/efeitos dos fármacos , Quinacrina/análogos & derivados , Quinacrina/síntese química , Animais , Western Blotting , Linhagem Celular Tumoral , Densitometria , Desenho de Fármacos , Imipramina/farmacologia , Indicadores e Reagentes , Ligantes , Camundongos , Proteínas PrPSc/química , Proteínas PrPSc/efeitos dos fármacos , Proteínas PrPSc/genética , Quinacrina/farmacologia , Relação Estrutura-AtividadeRESUMO
RATIONALE: 2-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213) is a highly selective antagonist at the dopamine D(4) receptor subtype. It was designed as a derivative of two partial antagonists and has been proven to be a complete antagonist in mitogenesis assay. OBJECTIVES: In the present study, FAUC 213 was examined for antipsychotic properties in animal models of behavioural neurobiology and neurochemistry. METHODS: Different concentrations of FAUC 213 were screened for effects on spontaneous, as well as amphetamine-induced, locomotor activity and apomorphine-induced prepulse disruption. The liability of causing extrapyramidal side effects was investigated in models of catalepsy and by high-performance liquid chromatography (HPLC) detection of dopamine turnover in several brain regions. The application schedule was validated, and the bioavailability of the compound determined, by means of a HPLC-pharmacokinetic study. RESULTS: A significant effect in both the reduction of amphetamine-induced locomotor hyperactivity and the restoration of apomorphine-disrupted prepulse inhibition was found at 30 mg/kg. This dose proved not to be high enough to induce catalepsy or to increase dopamine turnover in the dorsal striatum, nucleus accumbens and medial prefrontal cortex. The selective D(4) antagonist FAUC 213, therefore, is not believed to mediate the above-mentioned effects via D(2) receptor antagonism, but a partial involvement of 5-HT(2)- and alpha(1)-receptors cannot be ruled out at present. CONCLUSIONS: We have gathered evidence that FAUC 213 exhibits atypical antipsychotic characteristics.
Assuntos
Antagonistas dos Receptores de Dopamina D2 , Atividade Motora/efeitos dos fármacos , Neurônios/efeitos dos fármacos , Pirazóis/farmacologia , Piridinas/farmacologia , Esquizofrenia/tratamento farmacológico , Anfetamina , Animais , Encéfalo/metabolismo , Catalepsia/induzido quimicamente , Cromatografia Líquida de Alta Pressão , Modelos Animais de Doenças , Dopamina/metabolismo , Relação Dose-Resposta a Droga , Masculino , Neurônios/metabolismo , Pirazóis/administração & dosagem , Piridinas/administração & dosagem , Ratos , Ratos Wistar , Receptores de Dopamina D2/metabolismo , Receptores de Dopamina D4 , Reflexo de Sobressalto/efeitos dos fármacos , Esquizofrenia/metabolismo , Psicologia do Esquizofrênico , Fatores de TempoRESUMO
[reaction: see text] Highly efficient methodology for the construction of functionalized resins was presented involving 1,3-dipolar cycloaddition as the key reaction step. On the basis of this concept, the first series of click backbone amide linkers were synthesized and the application of the FIMT resin 3f to the parallel synthesis of putative dopaminergic agents was demonstrated leading to the selective receptor ligands 10i and 10s revealing high affinity to the D4 subtype.